In their paper, "Dermatologic Toxicities of Targeted Anticancer Therapies," Balagula and others provide a thorough discussion of cutaneous adverse events from newer, targeted anticancer agents. These agents include epidermal growth factor receptor (EGFR) inhibitors, as well as several other multikinase inhibitors. The authors describe the spectrum of skin, hair, and nail changes that arise from several such agents and comprehensively expound upon the psychosocial and physical discomfort of such toxicities.
|Original language||English (US)|
|Number of pages||2|
|Journal||Journal of Supportive Oncology|
|State||Published - Jul 1 2010|
ASJC Scopus subject areas
- Pharmacology (medical)